Last update April 16, 2024
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Quinapril Hydrochloride in other languages or writings:
Quinapril Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Quinapril Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 60 | % |
Molecular weight | 475 | daltons |
Protein Binding | 97 | % |
pKa | 3.7 | - |
Tmax | 2 | hours |
T½ | 3 | hours |
M/P ratio | 0.12 | - |
Relative Dose | 1.6 | % |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Quinapril, via its active metabolite, quinaprilat, is an angiotensin converting enzyme inhibitor (ACEI) used in the treatment of high blood pressure and heart failure. Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts. (Begg 2001)
No problems have been observed in infants whose mothers were taking other ACEIs. (Anderson 2018)
Expert authors consider the use of this drug acceptable during breastfeeding. (Hale, LactMed, Briggs 2015)
Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015)
The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)